Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 901–1,000 of 1,000
de Almeida, N. A., Baldoni, A. O., & Rios, D. R. A. (2022) · Medicina (Ribeirão Preto) · doi:10.11606/issn.2176-7262.rmrp.2022.194887 · Cited by 2
Khan, F. A., Thavorn, K., Coyle, D., van Katwyk, S., Tritschler, T., Hutton, B., Gal, G. L., Rodger, M. A., & Fergusson, D. A. (2023) · BMJ Open · doi:10.1136/bmjopen-2021-053927 · Cited by 2
Kang, H., Dietrich, E. A., Huang, P., Lo‐Ciganic, W., DeRemer, C. E., & Park, H. (2023) · Clinical and Translational Science · doi:10.1111/cts.13510 · Cited by 5
Blitz, S. E., Mashouf, L. A., Nieves, A., Matos, J. D., Yaffe, M. B., Davis, R. B., Alterman, R. L., & Stippler, M. (2023) · Neurosurgery · doi:10.1227/neu.0000000000002540 · Cited by 2
“20,21 The systematic algorithms for the use of AT in venous thromboembolism (VTE), cardiac stents, and AF are detailed in Figure 1.”
MethodSantini, P., Mosoni, C., D’Errico, A., Porceddu, E., Lupascu, A., Valeriani, E., Tondi, P., Pola, R., & Porfidia, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196427 · Cited by 2
“In detail, the numbers of cancer patients in the low-dose arms of the AMPILFY-EXT and EINSTEIN CHOICE trial were of 15 and 27, respectively [8,9].”
BackgroundGroat, D., Martin, K. A., Rosovsky, R. P. G., Sanfilippo, K. M., Gaddh, M., Kreuziger, L. B., Federici, E. H., & Woller, S. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010096 · Cited by 2
“…six months, reduced doses of apixaban (i.e., 2.5 mg twice daily) and rivaroxaban (i.e., 10 mg daily), when compared with initial treatment phase dose are equally safe and effective for the prevention of recurrent thrombosis and may be associated with a reduction in certain types of bleeding [8,10].”
BackgroundInfluentialChallenges, Recommendations, and Epidemiology of Pulmonary Embolism in India: A Narrative Review
Shetty, S. M., Vora, A. C., George, R. K., & Vidita, M. (2024) · Cureus · doi:10.7759/cureus.64195 · Cited by 2
“Anticoagulation therapy is the fundamental aspect of managing PE, with guideline recommendations on therapy extending up to 3 months or longer [4,28,29].”
BackgroundTelang, S. S., Palmer, R. C., Dobitsch, A. A., Ball, J. R., Heckmann, N. D., & Lieberman, J. R. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101548 · Cited by 2
Poli, D. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2441-8902 · Cited by 2
Ko, T., Wu, C., Hsieh, M., Yang, C., Cheng, C., Chen, C., & Kao, H. (2024) · Kidney International · doi:10.1016/j.kint.2024.10.023 · Cited by 7
Vallamkonda, B., Yarguntla, S. R., & Challa, R. R. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70043 · Cited by 2
Risk Factors and Management of Cancer-Associated Thrombosis
Vrotniakaite-Bajerciene, K., Carrier, M., & Wang, T. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.01.004 · Cited by 2
Barbosa, L., Oliveira, V. M. R., Araujo, B., Nunes, M. C. P., & Moreira, H. G. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.07.029 · Cited by 2
Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban
Eikelboom, J. W., & Connolly, S. J. (2015) · Cardiology Research · doi:10.14740/cr413w · Cited by 2
“5 mg BID) [20].”
Direct factor Xa inhibitor edoxaban: from bench to clinical practice
Brekelmans, M. P. A., Middeldorp, S., & Coppens, M. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1111756 · Cited by 4
Shantsila, E., & Lip, G. Y. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-25460-9_2 · Cited by 3
Rudakova, A. V. (2015) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2015-11-5-496-503 · Cited by 4
Management of Cancer-Associated Venous Thromboembolism in the Emergency Department
Nene, R. V., & Coyne, C. J. (2017) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.12.003 · Cited by 2
Evans, N. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-73709-6_5 · Cited by 3
Fatigue after initiating rivaroxaban for venous thromboembolism
Karlsvik, T. M., Borgenvik, T. L., Aadalen, M., Utne, K. K., Førsund, E., Jørgensen, C. T., Holst, R., Jelsness‐Jørgensen, L., Ghanima, W., & Kahn, S. R. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12312 · Cited by 2
Tumorassoziierte venöse Thromboembolie – Pathogenese, Diagnose, Prävention und Therapie
Riess, H. B. (2020) · best practice onkologie · doi:10.1007/s11654-020-00249-w · Cited by 2
Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method
Janknegt, R., Metting, E., Kooistra, J., & Dekhuijzen, R. P. N. (2020) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2020.04.0640 · Cited by 2
White, B. N., Patel, M. V. B., Ware, J., Cutshall, B. T., Sakaan, S. A., & Sawyer, A. (2022) · Hospital Pharmacy · doi:10.1177/00185787221115311 · Cited by 2
Statins during Anticoagulation for Emergency Life-Threatening Venous Thromboembolism: A Review
Siniscalchi, C., Imbalzano, E., Meschi, T., Ticinesi, A., Prati, B., Basaglia, M., Camporese, G., Perrella, A., Viorica, A., Eletto, E., et al. (2024) · Medicina · doi:10.3390/medicina60081240 · Cited by 4
Wu, X., Wang, H., Tan, X., Tan, X., Zhao, X., Liu, X., & Wang, W. (2024) · International Journal of Orthopaedic and Trauma Nursing · doi:10.1016/j.ijotn.2024.101155 · Cited by 2
Diagnostik und Therapie der akuten Lungenembolie
Hecker, M., Bayer, M., Krombach, G. A., & Sommer, N. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01249-w · Cited by 2
Derin Ven Trombozunda Güncel Tedaviler
Tekin, G. (2015) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.54870 · Cited by 3
Insights into direct anticoagulants
Saad, E., & Dally, N. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000291 · Cited by 2
Update in Pulmonary and Critical Care Medicine: Evidence Published in 2010
Heuser, R. G., Osborne, M. L., & Hall, J. R. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00339 · Cited by 2
Venous thromboembolism: Diagnosis, treatment and the prevention of long-term complications
Barnes, G. D., Froehlich, J. B., Kanthi, Y. M., & Wakefield, T. W. (2014) · Reviews in vascular medicine · doi:10.1016/j.rvm.2014.07.005 · Cited by 2
Les anticoagulants oraux directs en 2015 chez le patient âgé : focus chez le sujet fragile
Vogel, T., Andrès, E., Gény, B., Kaltenbach, G., & Lang, P. O. (2015) · Les cahiers de l année gérontologique · doi:10.1007/s12612-015-0460-8 · Cited by 3
“L’analyse à long terme (12 mois) contre placebo a été effectuée dans l’étude AMPLIFY-EXT [37] qui a comporté des sous-groupes de sujets de plus de 75 ans (329/2 482 [13,3 %]), des sujets avec une altération du DFG (< 80 ml/ min par 1,73 m ; 674/2 482 [27,1 %] et des sujets avec un poids inférieur ou égal à 60 kg (165/…”
BackgroundMookadam, M., Shamoun, F., Ramakrishna, H., Obeid, H., Rife, R., & Mookadam, F. (2015) · Annals of Cardiac Anaesthesia · doi:10.4103/0971-9784.166461 · Cited by 2
“Looking at the major clinically relevant and nonmajor bleeding, edoxaban had a favorable outlook and that led to the conclusion that edoxaban administered once daily offers a reasonable alternative treatment for patients with VTE.”
MethodInfluentialHoly, E. W., & Beer, J. H. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.001 · Cited by 2
“Extended treatment AMPLIFY-EXT study [12] was a randomized, double-blind trial that compared two doses of apixaban (2.”
MethodVenous Thromboembolism in the Elderly
Ali, M. S., & Czarnecka‐Kujawa, K. (2016) · Current Geriatrics Reports · doi:10.1007/s13670-016-0163-z · Cited by 2
Devabhakthuni, S., Yoon, C. H., & Pincus, K. J. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190014568388 · Cited by 2
Managing Extended Oral Anticoagulation After Unprovoked Venous Thromboembolism
Joseph, L., & Bartholomew, J. R. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416652236 · Cited by 2
“7]).(61,62) Notably, all bleeding rates were lower than the VKAs when used for extended VTE treatment.”
BackgroundMethodAn Algorithmic Approach to Management of Venous Thromboembolism
Dhakal, P., Gundabolu, K., & Bhatt, V. R. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616652727 · Cited by 4
“2%), compared to the treatment dose (5 mg twice daily).(13) Hence, we offer a prophylactic dose apixaban as an option to our patients.”
BackgroundUso de los anticoagulantes orales directos en la práctica clínica
Salamanca, R. G. J., Gómez, J. D. J., & Roa, A. E. P. (2016) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v64n2.49963 · Cited by 9
Meneveau, N. F. (2015) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2015.07.003 · Cited by 3
Direkt orális antikoagulánsok a kardiológiában
Kiss, R. G. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30578 · Cited by 2
Reversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015
Feistritzer, C., & Schmidt, S. U. (2016) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-016-0284-2 · Cited by 2
Piovella, F., & Iosub, D. I. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.12.001 · Cited by 3
Overview of the Direct Oral Anticoagulants
Skeik, N., Sethi, A. R., & Shepherd, M. F. (2017) · Journal of the Minneapolis Heart Institute Foundation · doi:10.21925/mplsheartjournal-d-16-00005 · Cited by 2
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes
Imberti, D., & Mastroiacovo, D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1688-7 · Cited by 2
2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants
Park, Y. M., Park, H. W., Lee, J., Park, J., Lee, K. H., Kim, J., Lee, Y. S., & Joung, B. (2019) · Korean Journal of Medicine · doi:10.3904/kjm.2019.94.1.57 · Cited by 2
“5 mg/dL) Dabigatran [25] 150 mg bid 110 mg bid: CrCl ≤ 50 mL/min or age ≥ 75 years Edoxaban [28] 60 mg qd 30 mg qd with one or more of the following: (weight ≤ 60 kg, CrCl ≤ 50 mL/min, concomitant use of a P-glycoprotein inhibitor) Rivaroxaban [26] 20 mg qd 15 mg qd: CrCl ≤ 50 mL/min or age ≥ 75-80 years Treatment of…”
Coagulation and Anticoagulants
Goubran, H. A., Bosch, M. J., & Stakiw, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-25782-8_1 · Cited by 2
Fitzmaurice, D. A., Fletcher, K., Greenfield, S., Jowett, S. M., Ward, A. M., Heneghan, C. J., Knight, E., Gardiner, C., Roalfe, A. K., Sun, Y., et al. (2020) · Programme Grants for Applied Research · doi:10.3310/pgfar08050 · Cited by 2
Beyer‐Westendorf, J., Marten, S., Tittl, L., Naue, C., & Bornhäuser, M. (2021) · TH Open · doi:10.1055/s-0041-1728675 · Cited by 2
Hafiz, A. M., Alshaya, A. I., Sylvester, K. W., Connors, J. M., & Rimsans, J. (2021) · Thrombosis Update · doi:10.1016/j.tru.2021.100076 · Cited by 2
Non-Vitamin K Antagonist Oral Anticoagulants
Shantsila, E., & Lip, G. Y. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-25460-9 · Cited by 3
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2018) · Springer eBooks · doi:10.1007/978-3-662-57386-0_18 · Cited by 4
Maladie thromboembolique veineuse
Monsuez, J. J. (2013) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(13)70489-9 · Cited by 2
Update in Pulmonary, Sleep, and Critical Care Medicine: Evidence Published in 2013
Balachandran, J. S., & Hall, J. B. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0209 · Cited by 2
“Prior work by these investigators (3) demonstrated that apixaban, an oral factor Xa inhibitor with rapid onset of action and fixed-dose administration, is effective for preventing recurrent VTE with low rates of major bleeding.”
BackgroundSarlon-Bartoli, G., Criado, J., Middeldorp, S., Nieto, J. A., Díaz-Pedroche, M. D. C., Moustafa, F., Ruiz‐Giménez, N., Brenner, B., Monréal, M., Micco, P. D., et al. (2023) · Thrombosis Update · doi:10.1016/j.tru.2023.100148 · Cited by 2
Clinical Implications of Co‐administering Apixaban with Key Interacting Medications
Favatella, N., Dalton, D., Byon, W., Merali, S. J., & Klem, C. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1446 · Cited by 2
Toth, P. P. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.912833 · Cited by 3
The use of new oral anticoagulants in surgery. Part 1
Пасечник, И. Н. (2016) · Pirogov Russian Journal of Surgery · doi:10.17116/hirurgia2016272-75 · Cited by 4
Aktuelle Therapie der akuten Lungenembolie
Keller, K., & Lankeit, M. (2019) · Der Pneumologe · doi:10.1007/s10405-019-0266-2 · Cited by 2
Anticoagulación en enfermedad tromboembólica venosa
Milena Morales, M., Luis Arboleda, R., & Ariel Bello, E. (2019) · Revista chilena de cardiología · doi:10.4067/s0718-85602019000200122 · Cited by 10
Sustained resolution of anticoagulation related iron deficiency anemia with the use of apixaban
Choo, A., Bragagnolo, A., Ekanayake, S., & Alghamry, A. (2019) · Clinical Case Reports · doi:10.1002/ccr3.2585 · Cited by 2
Post-Intensive Care Unit Follow-up of Pulmonary Embolism
Jasuja, S., & Channick, R. N. (2020) · Critical Care Clinics · doi:10.1016/j.ccc.2020.03.002 · Cited by 3
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients
Ravikumar, R., Lim, C. S., & Davies, A. H. (2016) · Advances in experimental medicine and biology · doi:10.1007/13780_2016_31 · Cited by 2
Comerota, A. J. (2018) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2018.03.011 · Cited by 2
ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
Gilyarov, M. Y., & Константинова, Е. В. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-7-56-62 · Cited by 2
Колбин, А. С., Kasimova, A. R., & Gilyarevskiy, S. R. (2023) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2022-4-38-49 · Cited by 2
Serrao, A., Ballotta, L., Dragoni, F., Pallotta, A., & Chistolini, A. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.10.020 · Cited by 2
Tapson, V. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00186-4 · Cited by 2
Kapur, V., & Goyal, S. M. (2023) · Wiley eBooks · doi:10.1002/9781119467779.ch14 · Cited by 2
Reardon, D. P., & Zemaitis, C. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-71240-6_10 · Cited by 1
Was der (Allgemein- und Viszeral‑)Chirurg über die Thromboseprophylaxe wissen sollte
Meißler, S., Braun-Dullaeus, R. C., Hansen, M., & Meyer, F. (2022) · Die Chirurgie · doi:10.1007/s00104-021-01568-6 · Cited by 1
Ганцгорн, Е. В., Сафроненко, А. В., Gubin, E. V., Vlasenko, V. A., Rashkova, E. V., Маллеев, И. М., Ivanov, A. V., Герасюта, С. С., Bulguryan, G. A., Осипенко, Я. О., et al. (2023) · Journal Biomed · doi:10.33647/2074-5982-19-2-37-44 · Cited by 3
Anticoagulation in patients with inferior vena cava agenesia
Cires-Drouet, R. S. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00167-4 · Cited by 1
Villalobos, A., Valle, R., Escribano, J. P., Ortiz, M., Rodríguez, P. D., & Font, C. (2024) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2024.10.007 · Cited by 1
Anticoagulation for extended venous thromboembolism treatment: less is really more
Middeldorp, S., & Leentjens, J. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00099-6 · Cited by 1
Васильевна, С. О., Громова, Е. Г., Львовна, Е. А., & Валентиновна, Б. И. (2025) · Podderživaûŝaâ terapiâ v onkologii. · doi:10.17650/3034-2473-2025-2-1-58-65 · Cited by 1
Tone, S., Naito, Y., Wakabayashi, H., Sudo, A., & Hasegawa, M. (2025) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-025-04291-8 · Cited by 1
“[16].”
Foss, V., Celebi, T. B., Waheed, R., & Dhillon, H. (2025) · Cureus · doi:10.7759/cureus.87748 · Cited by 1
“Hematomas have been illustrated in the AMPLIFY and AMPLIFY-EXT study to occur in 1.3% -2.0% of cases when being treated for deep vein thrombosis (DVT) and pulmonary embolism (PE), though size and location have always been irregular [7,8].”
InfluentialDiagnostik und Therapie der akuten Lungenembolie
Hecker, M., Bayer, M., Krombach, G. A., & Sommer, N. (2025) · Die Radiologie · doi:10.1007/s00117-025-01505-2 · Cited by 1
Bardetta, M., Simoncini, M., Valeri, F., Pizzuto, A., Dainese, C., Sella, C., Porreca, A., Bruno, B., & Borchiellini, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14175991 · Cited by 2
Albukhari, A. F., AlHarbi, Y., Alqahtani, M. M., Hageen, A. W., Ibrahim, A. A., Alhomidani, F., Alshammari, T. G., Albalawi, T., Alshehri, S., Alayidh, M. A., et al. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2554467 · Cited by 3
Valeriani, E., Pannunzio, A., Brogi, T., Palumbo, I., Menichelli, D., Marucci, S., Tretola, L., Mastroianni, C. M., Pastori, D., & Pignatelli, P. (2025) · Diagnostics · doi:10.3390/diagnostics15172283 · Cited by 1
“Considering the risk of recurrent VTE as maximum in the first year after the index event, the results of these two trials are extremely useful [5,11,12].”
InfluentialSafety and optimal use of direct oral anticoagulant therapy
Laudani, C., Ortega‐Paz, L., Zgheib, A., Khoury, G. E., Alawajneh, M. M., Farahmandsadr, M., Capodanno, D., & Angiolillo, D. J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586121 · Cited by 2
Zhang, R., Wang, R., Li, Y., Tian, W., Niu, D., Cheng, W., & Niu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1708316 · Cited by 1
Managing patients with a history of arterial disease and new venous thromboembolism
Deng, E., & Passam, F. H. (2025) · Hematology · doi:10.1182/hematology.2025000683 · Cited by 1
Anticoagulation in malignancy: the patient who bleeds and clots simultaneously
Kapoor, S., Peseski, A. M., & Ortel, T. L. (2025) · Hematology · doi:10.1182/hematology.2025000703 · Cited by 1
Deng, D., Xu, Z., & Zhu, W. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251408061 · Cited by 1
“8,10 This suggests that dose reduction may not substantially compromise thromboprophylactic ef fi cacy, even in high-risk populations such as those with unpro-voked VTE or severe initial presentations.”
InfluentialCohen, A. T., Choudhuri, S., Khan, I., Pollock, K. G., Bober-Irizar, M., Galias, Z., Irizar, A., & Bober, M. Z. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.06.015 · Cited by 1
Self-citationBrandão, L. R., Driscoll, J., Newburger, J. W., Holzhauer, S., Ahuja, S., Rubio, A. E., Gaitonde, P., Robertson, A., Polinsky, M., Revkin, J. H., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00107-9 · Cited by 1
Scheres, L. J. J., Weyand, A. C., Baldwin, M. K., Thachil, J. V., Othman, M., Middeldorp, S., Achebe, M., Kadir, R. A., Áinle, F. N., Akaba, G. O., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00079-7 · Cited by 3
Optimal duration of anticoagulant therapy in patients with venous thromboembolism
Palareti, G. (2018) · Italian Journal of Medicine · doi:10.4081/item.2018.1077 · Cited by 1
Kimmerle, A., Noflatscher, M., & Raggam, R. B. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001106 · Cited by 2
“While assessing the individual risk of the patient, biomarkers can contribute to an informed decision.”
Mühlbauer, B., & Wille, H. (2025) · Springer eBooks · doi:10.1007/978-3-662-70594-0_9 · Cited by 1
LYRA, G. O. T., Katsuyama, E. S., Pincelli, M. P., de Almeida, V. P., Prado, M. L. D. L., Pereira, S. B., Tinoco, J. A., Nunes, M. A. P., & Fernandes, C. J. C. D. S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.12.012 · Cited by 2
Unmet Needs and Challenges in Cancer-Associated Venous Thromboembolism
Nusrat, S., Khan, S., Beg, K. A., & Raskob, G. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041756 · Cited by 1
“Within the general population, secondary prophylaxis with reduced-dose apixaban (2.5 mg twice daily) and rivaroxaban (10 mg daily) has been demonstrated to be protective against recurrent VTE without significantly increasing the rate of major bleeding— showcasing efficacy and safety [138,139].”
InfluentialSelf-citationJeong, J., Ah, Y., Han, J. M., Min, S., Shin, J., Heo, K., & Lee, J. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.01.018 · Cited by 2
Ali, M. F., Naseer, F., Hageen, A. W., Hayat, S., Rashid, Z., Momna, F. N. U., Sawaira, F., Riaz, A. A., Ahmad, H. F., Eltawansy, S., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70142 · Cited by 1
Malte, A. L., Abilgaard, A. M., Højbjerg, J. A., Hellfritzsch, M., Grove, E. L., & Larsen, J. B. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109759 · Cited by 2
Practical recommendations on incorporating new oral anticoagulants into routine practice.
Randhawa, J. S., Thiruchelvam, N., Ghobrial, M., Spiro, T. P., Clark, B. A., Haddad, A. S., & Daw, H. A. (2014) · PubMed · Cited by 1
Novel Oral Anticoagulants for Stroke Prophylaxis and Venous Thromboembolism Prevention and Treatment
Alsayegh, L. G. (2015) · Journal of patient-centered research and reviews · doi:10.17294/2330-0698.1055 · Cited by 1
Blickstein, D., Eliakim‐Raz, N., & Gafter‐Gvili, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011088 · Cited by 1
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.